Misspecification of Cox regression models with composite endpoints.
about
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary FibrosisBalancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Bias in progression-free survival analysis due to intermittent assessment of progression.A DAG-based comparison of interventional effect underestimation between composite endpoint and multi-state analysis in cardiovascular trials.
P2860
Misspecification of Cox regression models with composite endpoints.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Misspecification of Cox regression models with composite endpoints.
@en
Misspecification of Cox regression models with composite endpoints.
@nl
type
label
Misspecification of Cox regression models with composite endpoints.
@en
Misspecification of Cox regression models with composite endpoints.
@nl
prefLabel
Misspecification of Cox regression models with composite endpoints.
@en
Misspecification of Cox regression models with composite endpoints.
@nl
P2860
P356
P1476
Misspecification of Cox regression models with composite endpoints.
@en
P2093
Longyang Wu
Richard J Cook
P2860
P304
P356
10.1002/SIM.5436
P407
P577
2012-06-27T00:00:00Z